Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of β-cells

American Journal of Physiology - Endocrinology and Metabolism

Volumn 287, Issue 4 50-4, 2004, Pages

  Haugaard, Steen B ^a   Andersen, Ove ^a   Storgaard, Heidi ^b   Dela, Flemming ^c   Holst, Jens Juul ^c   Iversen, Johan ^a   Nielsen, Jens Ole ^a   Madsbad, Sten ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Human immunodeficiency virus; Nonglucose insulin secretagogues

Indexed keywords

ALANINE; C PEPTIDE; FATTY ACID; GLUCAGON; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIET RESTRICTION; EVALUATION; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NEGATIVE FEEDBACK; PANCREAS ISLET BETA CELL; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPOSE TISSUE; ADULT; ALANINE; ANTHROPOMETRY; BLOOD GLUCOSE; BODY COMPOSITION; BODY MASS INDEX; C-PEPTIDE; FEEDBACK; GLUCAGON; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 4544318076     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00009.2004     Document Type: Article

References (44)

1. Ahmed M, Grapengiesser E, and Hillman B. Amino acid transformation of oscillatory Ca2+ signals in mouse pancreatic beta-cells. J Endocrinol 160: 191-195, 1999.
2. Andersen O, Haugaard SB, Andersen UB, Friis-Moller N, Storgaard H, Volund A, Nielsen JO, Iversen J, and Madsbad S. Lipodystrophy in human immunodeficiency virus patients: impairs insulin action and induces, defects in beta-cell function. Metabolism 52: 1343-1353, 2003.
3. Argoud GM, Schade DS, and Eaton RP. Insulin suppresses its own secretion in vivo. Diabetes 36: 959-962, 1987.
4. Balasse EO and Ooms HA. Role of plasma free fatty acids in the control of insulin secretion in man. Diabetologia 9: 145-151, 1973.
5. Bernasconi E, Boubaker K, Junghans C, Flepp M, Furrer HJ, Haensel A, Hirschel B, Boggian K, Chave JP, Opravil M, Weber R, Rickenbach M, and Telenti A. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 31: 50-55, 2002.
6. Boden G and Chen X. Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. Diabetes 48: 577-583, 1999.
7. Boden G, Chen X, Rosner J, and Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 44: 1239-1242, 1995.
8. Boufassa F, Dulioust A, Lascaux AS, Meyer L, Boue F, Delfraissy JF, Sobel A, and Goujard C. Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin Trials 2: 339-345, 2001.
9. Bratusch-Marrain PR and Waldbausl WK. Suppression of basal, but not of glucose-stimulated insulin secretion by human insulin in healthy and obese hyperinsulinemic subjects. Metabolism 34: 188-193, 1985.
10. Brennan L, Shine A, Hewage C, Malthouse JP, Brindle KM, McClenaghan N, Flatt PR, and Newsholme P. A nuclear magnetic resonance-based demonstration of substantial oxidative L-alanine metabolism and L-alanine-enhanced glucose metabolism in a clonal pancreatic beta-cell line: metabolism of L-alanine is important to the regulation of insulin secretion. Diabetes 51: 1714-1721, 2002.
11. Carr A, Emery S, Law M, Puls R, Lundgren JD, and Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361: 726-735, 2003.
12. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, and Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58, 1998.
13. DeFronzo RA, Binder C, Wahren J, Felig P, Ferrannini E, and Faber OK. Sensitivity of insulin secretion to feedback inhibition by hyperinsulinaemia. Acta Endocrinol (Copenh) 98: 81-86, 1981.
14. Fogh-Andersen N and D'Orazio P. Proposal for standardizing direct-reading biosensors for blood glucose. Clin Chem 44: 655-659, 1998.
15. Greenough WB III, Crespin SR, and Steinberg D. Hypoglycaemia and hyperinsulinaemia in response to raised free-fatty-acid levels. Lancet 2: 1334-1336, 1967.
16. Heath KV, Hogg RS, Singer J, Chan KJ, O'Shaughnessy MV, and Montaner JS. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort. J Acquir Immune Defic Syndr 30: 440-447, 2002.
17. Holst JJ. Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours. Diabetologia 24: 359-365, 1983.
18. Hother-Nielsen O, Henriksen JE, Holst JJ, and Beck-Nielsen H. Effects of insulin on glucose turnover rates in vivo: isotope dilution versus constant specific activity technique. Metabolism 45: 82-91, 1996.
19. Hovorka R, Koukkou E, Southerden D, Powrie JK, and Young MA. Measuring pre-hepatic insulin secretion using a population model of C-peptide kinetics: accuracy and required sampling schedule. Diabetologia 41: 548-554, 1998.
20. Hovorka R, Soons PA, and Young MA. ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 50: 253-264, 1996.
21. Hruz PW, Murata H, Qiu H, and Mueckler M. Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 51: 937-942, 2002.
22. Huypens P, Ling Z, Pipeleers D, and Schuit F. Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 43: 1012-1019, 2000.
23. Iozzo P, Beck-Nielsen H, Laakso M, Smith U, Yki-Jarvinen H, and Ferrannini E. Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance. J Clin Endocrinol Metab 84: 863-868, 1999.
24. Jensen CB, Storgaard H, Dela F, Holst JJ, Madsbad S, and Vaag AA. Early differential defects of insulin secretion and action in 19-year-old Caucasian men who had low birth weight. Diabetes 51: 1271-1280, 2002.
25. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, and Palmer JP. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42: 1663-1672, 1993.
26. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarine L, DeFronzo R, and Cusi K. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 52: 2461-2474, 2003.
27. Kjems LL, Volund A, and Madsbad S. Quantification of beta-cell function during IVGTT in Type II and non-diabetic subjects: assessment of insulin secretion by mathematical methods. Diabetologia 44: 1339-1348, 2001.
28. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, Stamm ER, Scherzinger AL, and Eckel RH. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 15: 1993-2000, 2001.
29. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, and Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96: 329-339, 1999.
30. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, Blanchi L, Conget I, Blanch J, Phillips A, and Gatell JM. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357: 592-598, 2001.
31. McGarry JD and Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42: 128-138, 1999.
32. Moens K, Berger V, Ahn JM, Van Schravendijk C, Hruby VJ, Pipeleers D, and Schuit F. Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic beta-cells. Diabetes 51: 669-675, 2002.
33. Nesher R and Cerasi E. Modeling phasic insulin release: immediate and time-dependent effects of glucose. Diabetes 51, Suppl 1: S53-S59, 2002.
34. Nyholm B, Walker M, Gravholt CH, Shearing PA, Sturis J, Alberti KG, Hoist JJ, and Schmitz O. Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. Diabetologia 42: 1314-1323, 1999.
35. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, Dailey G, and Gerich J. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 273: 1855-1861, 1995.
36. Polonsky KS, Given BD, and Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 81: 442-448, 1988.
37. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, Lang JM, Gastaut JA, and Touraine JL. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 14: 37-49, 2000.
38. Saves M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, Basdevant A, Leport C, and Chene G. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 34: 1396-1405, 2002.
39. Stein DT, Esser V, Stevenson BE, Lane KE, Whiteside JH, Daniels MB, Chen S, and McGarry JD. Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J Clin Invest 97: 2728-2735, 1996.
40. Storgaard H, Jensen CB, Vaag AA, Volund A, and Madsbad S. Insulin secretion after short- and long-term low-grade free fatty acid infusion in men with increased risk of developing type 2 diabetes. Metabolism 52: 885-894, 2003.
41. Sutinen J, Hakkinen AM, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Halavaara J, Jarvinen A, Ristola M, and Yki-Jarvinen H. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 16: 2183-2193. 2002.
42. Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, and Groop LC. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes 49: 975-980, 2000.
43. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44: 863-870, 1995.
44. Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL, and Gerich JE. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 52: 918-925, 2003.